Everolimus, an mTOR pathway inhibitor, is highly successful on ovarian hyperstimulation syndrome by reducing ovarian weight and progesterone levels: a preclinical experimental randomized controlled study. Επικοινωνία Submitted by Δημήτρης Σπάχος on Πέμ, 04/21/2016 - 11:38
